Skip to main content
. Author manuscript; available in PMC: 2018 Nov 15.
Published in final edited form as: J Immunol. 2017 Oct 4;199(10):3504–3515. doi: 10.4049/jimmunol.1700289

Figure 2. TCDD treatment decreased the percentage of the CD10+ cell population during B lymphopoiesis.

Figure 2

Cord blood-derived human CD34+ HSPCs were treated with vehicle (VH, 0.02% DMSO) or TCDD (0.01, 0.1, 1 or 10 nM) on day 0 and cultured for up to 28 days. Cells were harvested on day 14, 21 and 28. The percentage of the CD10+ cell population was assessed by flow cytometry, which includes common lymphoid progenitors (CLP) (CD10+ CD79α− CD19−), early-B cells (CD10+ CD79α+ CD19−) and pro-B cells (CD10+ CD79α+ CD19+). Data are presented as mean ± SE of triplicate measurements. Data are representative of three independent experiments with similar results.